Intellia Therapeutics Inc buy Royal Bank of Canada
Start price
10.11.23
/
50%
€22.58
Target price
10.11.24
€65.49
Performance (%)
-7.40%
Price
28.05.24
€20.91
Summary
This prediction is currently active. With a performance of -7.40%, the BUY prediction for Intellia Therapeutics Inc by Royal_Bank_of_Canada is down slightly. This prediction currently runs until 10.11.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Intellia Therapeutics Inc | -11.660% | -11.660% |
iShares Core DAX® | -0.448% | 2.344% |
iShares Nasdaq 100 | 0.834% | 5.019% |
iShares Nikkei 225® | -0.479% | 0.550% |
iShares S&P 500 | -0.352% | 2.631% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Royal Bank of Canada from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat